Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 18, Issue 11, pp. 1909-1915
PubMed
Published By
Print ISSN
Online ISSN
History
- Received March 7, 2019
- Revision received June 11, 2019
- Accepted September 4, 2019
- Published first November 1, 2019.
Copyright & Usage
©2019 American Association for Cancer Research.
Author Information
- Nabil F. Saba1,*,
- Zhuo Gerogia Chen1,
- Missak Haigentz2,
- Paolo Bossi3,
- Alessandra Rinaldo4,
- Juan P. Rodrigo5,
- Antti A. Mäkitie6,
- Robert P. Takes7,
- Primoz Strojan8,
- Jan B. Vermorken9, and
- Alfio Ferlito10
- 1Department of Hematology and Medical oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia.
- 2Atlantic Health System, Morristown, New Jersey.
- 3Medical Oncology Department, University of Brescia, Brescia, Italy.
- 4University of Udine School of Medicine, Udine, Italy.
- 5Hospital Universitario Central de Asturias, Oviedo, Spain.
- 6Department of Otorhinolaryngology–Head and Neck Surgery, University of Helsinki and HUS Helsinki University Hospital, Helsinki, Finland.
- 7Radboud University Medical Center, Nijmegen, the Netherlands.
- 8Institute of Oncology, Ljubljana, Slovenia.
- 9Antwerp University Hospital, Edegem, Belgium.
- 10Coordinator of the International Head and Neck Scientific Group, Padua, Italy.
- ↵*Corresponding Author:
Nabil F. Saba, Winship Cancer Institute, Emory University, 1365 Clifton Road NE, Building C, Atlanta, GA 30322. Phone: 404-778-3126; Fax: 404-778-5676; E-mail: nfsaba{at}emory.edu
November 2019
Volume 18, Issue 11
Volume 18, Issue 11
Targeting the EGFR and Immune Pathways in Squamous Cell Carcinoma of the Head and Neck (SCCHN): Forging a New Alliance
Jump to section
- Article
- Abstract
- Rationale for Inhibiting EGFR in SCCHN
- The Limitations of Anti-EGFR Targeting in SCCHN
- Resistance Mechanisms to EGFR Inhibition
- Emergence of Immunotherapy as an Effective Therapeutic Modality in SCCHN
- Immune Implications of EGFR Targeting
- Forging the Alliance
- Disclosure of Potential Conflicts of Interest
- Acknowledgments
- Footnotes
- References
- Figures & Data
- Info & Metrics
Advertisement